ENTRY       K16172                      KO
NAME        IRS1
DEFINITION  insulin receptor substrate 1
PATHWAY     ko04022  cGMP-PKG signaling pathway
            ko04068  FoxO signaling pathway
            ko04150  mTOR signaling pathway
            ko04151  PI3K-Akt signaling pathway
            ko04152  AMPK signaling pathway
            ko04722  Neurotrophin signaling pathway
            ko04910  Insulin signaling pathway
            ko04920  Adipocytokine signaling pathway
            ko04930  Type II diabetes mellitus
            ko04932  Non-alcoholic fatty liver disease (NAFLD)
            ko04960  Aldosterone-regulated sodium reabsorption
            ko05206  MicroRNAs in cancer
BRITE       KEGG Orthology (KO) [BR:ko00001]
             Environmental Information Processing
              Signal transduction
               04068 FoxO signaling pathway
                K16172  IRS1; insulin receptor substrate 1
               04022 cGMP - PKG signaling pathway
                K16172  IRS1; insulin receptor substrate 1
               04151 PI3K-Akt signaling pathway
                K16172  IRS1; insulin receptor substrate 1
               04152 AMPK signaling pathway
                K16172  IRS1; insulin receptor substrate 1
               04150 mTOR signaling pathway
                K16172  IRS1; insulin receptor substrate 1
             Organismal Systems
              Endocrine system
               04910 Insulin signaling pathway
                K16172  IRS1; insulin receptor substrate 1
               04920 Adipocytokine signaling pathway
                K16172  IRS1; insulin receptor substrate 1
              Excretory system
               04960 Aldosterone-regulated sodium reabsorption
                K16172  IRS1; insulin receptor substrate 1
              Nervous system
               04722 Neurotrophin signaling pathway
                K16172  IRS1; insulin receptor substrate 1
             Human Diseases
              Cancers
               05206 MicroRNAs in cancer
                K16172  IRS1; insulin receptor substrate 1
              Endocrine and metabolic diseases
               04930 Type II diabetes mellitus
                K16172  IRS1; insulin receptor substrate 1
               04932 Non-alcoholic fatty liver disease (NAFLD)
                K16172  IRS1; insulin receptor substrate 1
GENES       HSA: 3667(IRS1)
            PTR: 459985(IRS1)
            PPS: 100971596(IRS1)
            GGO: 101132740(IRS1)
            PON: 100442255(IRS1)
            MCC: 707870(IRS4)
            MCF: 102117978(IRS1)
            MMU: 16367(Irs1)
            RNO: 25467(Irs1)
            CGE: 100755710(Irs1)
            HGL: 101708189(Irs1)
            TUP: 102496620(IRS1)
            CFA: 486148(IRS1)
            FCA: 101087257(IRS1)
            PTG: 102965599(IRS1)
            BTA: 538598(IRS1)
            BOM: 102284664(IRS1)
            PHD: 102316951(IRS1)
            CHX: 102184858(IRS1)
            SSC: 100512686(IRS1)
            CFR: 102512682(IRS1)
            BACU: 103011761(IRS1)
            LVE: 103074278(IRS1)
            ECB: 100061987(IRS1)
            MYB: 102247525(IRS1)
            MYD: 102752666(IRS1)
            PALE: 102891583(IRS1)
            MDO: 100021838(IRS1)
            SHR: 100918116(IRS1)
            GGA: 101749888(IRS1) 429262(IRS1)
            MGP: 100539255
            TGU: 100220553(IRS1)
            FAB: 101810426(IRS1)
            PHI: 102101540(IRS1)
            APLA: 101797251(IRS1)
            FPG: 101922249(IRS1)
            FCH: 102052001(IRS1)
            CLV: 102083619(IRS1)
            ASN: 102372136(IRS1)
            AMJ: 102574179(IRS1)
            PSS: 102455771 102463626(IRS1)
            CMY: 102945843(IRS1)
            ACS: 100565100
            PBI: 103048511 103055013(IRS1)
            XLA: 399299(irs1)
            XTR: 100495320
            DRE: 559281(irs1)
            TRU: 101069368 101072794
            MZE: 101464741 101471414
            OLA: 101163034 101165750
            XMA: 102224423 102227908
            LCM: 102366510 102367331
            CMK: 103180489(irs1)
            BFO: BRAFLDRAFT_124878 BRAFLDRAFT_132514
            CIN: 100185541
            SPU: 100890677
            DME: Dmel_CG5686(chico)
            DPO: Dpse_GA19056
            DAN: Dana_GF14127
            DER: Dere_GG23965
            DPE: Dper_GL18973
            DSE: Dsec_GM11923
            DSI: Dsim_GD22290
            DWI: Dwil_GK10422
            DYA: Dyak_GE26285
            DGR: Dgri_GH25312
            DMO: Dmoj_GI10661 Dmoj_GI10672
            DVI: Dvir_GJ14922
            AME: 408438(IRS)
            NVI: 100119908
            BMOR: 101745072
            API: 100569479
            PHU: Phum_PHUM441290
            CEL: CELE_C54D1.3(ist-1)
            CBR: CBG10979(Cbr-ist-1)
            BMY: Bm1_00475
            LOA: LOAG_01973
            TSP: Tsp_03690
            NVE: NEMVE_v1g92099
            TPS: THAPSDRAFT_2942
REFERENCE   PMID:17591841
  AUTHORS   Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, Reiss K, Garcia M, Russo A, Ando S, Surmacz E
  TITLE     The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.
  JOURNAL   Ann Oncol 18 Suppl 6:vi81-5 (2007)
///
